Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply.

Autor: Danese S; IRCCS Ospedale San Raffaele and University Vita-Salute, San Raffaele, Milan, Italy., Levesque BG; Gossamer, Bio, Inc., San Diego, California, USA., Feagan BG; Alimentiv Inc., London, ON, Canada., Jucov A; ARENSIA Exploratory Medicine GmbH, Düsseldorf, Germany., Bhandari BR; Nicolae Testemitanu State University of Medicine and Pharmacy, Chișinău, Moldova.; Delta Research Partners, Bastrop, Los Angeles, USA., Pai RK; Mayo Clinic, Phoneix, Arizona, USA., Meadows KT; Gossamer, Bio, Inc., San Diego, California, USA., Kirby BJ; Gossamer, Bio, Inc., San Diego, California, USA., Bruey JM; Gossamer, Bio, Inc., San Diego, California, USA., Olson A; Gossamer, Bio, Inc., San Diego, California, USA., Osterhout R; Gossamer, Bio, Inc., San Diego, California, USA., Van Biene C; Gossamer, Bio, Inc., San Diego, California, USA., Ford J; Gossamer, Bio, Inc., San Diego, California, USA., Aranda R; Gossamer, Bio, Inc., San Diego, California, USA., Raghupathi K; Gossamer, Bio, Inc., San Diego, California, USA., Sandborn WJ; University of California San Diego, La Jolla, California, USA.

Publikováno v: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Mar; Vol. 55 (6), pp. 735-736.